Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 17M | 21M | 14M | 2M |
| Gross Profit | 0 | 2M | 7M | 4M | 334K |
| Operating Income | -4M | -7M | -14M | -10M | -22M |
| EBITDA | -4M | 329K | -6M | -7M | -25M |
| Net Income | -19M | -17M | -64M | -11M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stem Holdings, Inc. (STMH) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +11.9%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +11.9%, free cash flow +81.5% with operating margin 0.0% and ROIC -26.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STMH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STMH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STMH Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STMH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.5M
-82.5% YoY
FY Net Income
-$28.6M
-159.9% YoY
Free Cash Flow
-$7.9M
-44.1% YoY
Revenue Growth
-100.0%
EPS Growth
+11.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 17M | 21M | 14M | 2M |
| Gross Profit | 0 | 2M | 7M | 4M | 334K |
| Operating Income | -4M | -7M | -14M | -10M | -22M |
| EBITDA | -4M | 329K | -6M | -7M | -25M |
| Net Income | -19M | -17M | -64M | -11M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 961K | 2M | 6M | 2M | 3M |
| Total Assets | 13M | 31M | 57M | 45M | 31M |
| Total Liabilities | 14M | 14M | 23M | 18M | 8M |
| Shareholder Equity | -2M | 16M | 33M | 25M | 24M |
| Total Debt | 2M | 11M | 12M | 13M | 6M |
| Net Debt | 1M | 10M | 7M | 11M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
-30.3% YoY
Capital Expenditures
1M
-191.9% YoY
Free Cash Flow
8M
-44.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-274.8%
Debt / Equity
-1.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.